AU2018290766A1 - Peripheral nerve stimulation device for affecting parasympathetic and sympathetic activity to achieve therapeutic effects - Google Patents
Peripheral nerve stimulation device for affecting parasympathetic and sympathetic activity to achieve therapeutic effects Download PDFInfo
- Publication number
- AU2018290766A1 AU2018290766A1 AU2018290766A AU2018290766A AU2018290766A1 AU 2018290766 A1 AU2018290766 A1 AU 2018290766A1 AU 2018290766 A AU2018290766 A AU 2018290766A AU 2018290766 A AU2018290766 A AU 2018290766A AU 2018290766 A1 AU2018290766 A1 AU 2018290766A1
- Authority
- AU
- Australia
- Prior art keywords
- electrical signal
- patient
- electrode
- ear
- khz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002889 sympathetic effect Effects 0.000 title claims abstract description 61
- 230000001734 parasympathetic effect Effects 0.000 title claims abstract description 57
- 210000000578 peripheral nerve Anatomy 0.000 title claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
- 230000007383 nerve stimulation Effects 0.000 title claims description 19
- 230000000638 stimulation Effects 0.000 claims abstract description 275
- 238000000034 method Methods 0.000 claims abstract description 109
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 65
- 230000003287 optical effect Effects 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 5
- 230000001537 neural effect Effects 0.000 claims description 67
- 239000000090 biomarker Substances 0.000 claims description 55
- 238000002560 therapeutic procedure Methods 0.000 claims description 53
- 210000005036 nerve Anatomy 0.000 claims description 52
- 230000000694 effects Effects 0.000 claims description 43
- 230000007423 decrease Effects 0.000 claims description 37
- 230000000770 proinflammatory effect Effects 0.000 claims description 35
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 241000746998 Tragus Species 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 230000000747 cardiac effect Effects 0.000 claims description 13
- 210000003403 autonomic nervous system Anatomy 0.000 claims description 12
- 230000001766 physiological effect Effects 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 9
- 230000002567 autonomic effect Effects 0.000 claims description 9
- 210000005069 ears Anatomy 0.000 claims description 9
- 238000006213 oxygenation reaction Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 229960002964 adalimumab Drugs 0.000 claims description 6
- 229960000598 infliximab Drugs 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 238000002106 pulse oximetry Methods 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 4
- -1 IFN-a Proteins 0.000 claims description 4
- 102000003810 Interleukin-18 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010012305 Demyelination Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 3
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
- 229960003697 abatacept Drugs 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000037005 anaesthesia Effects 0.000 claims description 3
- 229960004238 anakinra Drugs 0.000 claims description 3
- 230000002146 bilateral effect Effects 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 230000028709 inflammatory response Effects 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical group C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002329 methacholine Drugs 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 208000022925 sleep disturbance Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 230000002861 ventricular Effects 0.000 claims description 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 102100032752 C-reactive protein Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229920001940 conductive polymer Polymers 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 238000001429 visible spectrum Methods 0.000 claims description 2
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 238000012517 data analytics Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 7
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 210000002820 sympathetic nervous system Anatomy 0.000 abstract description 3
- 210000001002 parasympathetic nervous system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 10
- 210000003484 anatomy Anatomy 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 230000001515 vagal effect Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000013186 photoplethysmography Methods 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000000613 ear canal Anatomy 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000002979 radial nerve Anatomy 0.000 description 4
- 206010027603 Migraine headaches Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002802 cardiorespiratory effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000010473 Hoarseness Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000004070 electrodeposition Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 2
- 229940125389 long-acting beta agonist Drugs 0.000 description 2
- 210000001699 lower leg Anatomy 0.000 description 2
- 210000001595 mastoid Anatomy 0.000 description 2
- 230000025350 membrane depolarization involved in regulation of action potential Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 230000037053 non-rapid eye movement Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 210000000658 ulnar nerve Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000027036 Hippa Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010065508 Orthostatic hypertension Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 229940098165 atrovent Drugs 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009910 autonomic response Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008701 parasympathetic activation Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940125390 short-acting beta agonist Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 230000002602 somatotopic effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000007384 vagal nerve stimulation Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36031—Control systems using physiological parameters for adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36034—Control systems specified by the stimulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36036—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
- A61N1/36139—Control systems using physiological parameters with automatic adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0605—Ear
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762525151P | 2017-06-26 | 2017-06-26 | |
| US62/525,151 | 2017-06-26 | ||
| US201762576440P | 2017-10-24 | 2017-10-24 | |
| US62/576,440 | 2017-10-24 | ||
| PCT/US2018/039467 WO2019005774A1 (en) | 2017-06-26 | 2018-06-26 | DEVICE FOR STIMULATING PERIPHERAL NERVE TO MODIFY PARASYMPATHIC AND SYMPATHETIC ACTIVITY TO OBTAIN THERAPEUTIC EFFECTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018290766A1 true AU2018290766A1 (en) | 2020-01-02 |
Family
ID=64741875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018290766A Abandoned AU2018290766A1 (en) | 2017-06-26 | 2018-06-26 | Peripheral nerve stimulation device for affecting parasympathetic and sympathetic activity to achieve therapeutic effects |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200261722A1 (https=) |
| EP (1) | EP3618919A4 (https=) |
| JP (1) | JP2020525252A (https=) |
| CN (1) | CN111447969A (https=) |
| AU (1) | AU2018290766A1 (https=) |
| WO (1) | WO2019005774A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3498332B1 (en) | 2013-01-21 | 2021-07-14 | Cala Health, Inc. | Devices for controlling tremor |
| US12453853B2 (en) | 2013-01-21 | 2025-10-28 | Cala Health, Inc. | Multi-modal stimulation for treating tremor |
| AU2015271774B2 (en) | 2014-06-02 | 2020-04-16 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation to treat tremor |
| CN119565022A (zh) | 2015-06-10 | 2025-03-07 | 卡拉健康公司 | 用于外周神经刺激以利用可拆卸治疗和监测单元治疗震颤的系统和方法 |
| WO2017023864A1 (en) | 2015-07-31 | 2017-02-09 | Cala Health, Inc. | Systems, devices, and method for the treatment of osteoarthritis |
| EP3352843B1 (en) | 2015-09-23 | 2021-06-23 | Cala Health, Inc. | Device for peripheral nerve stimulation in the finger to treat hand tremors |
| WO2017132067A2 (en) | 2016-01-21 | 2017-08-03 | Cala Health, Inc. | Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder |
| JP6726318B2 (ja) * | 2016-03-09 | 2020-07-22 | ストッパーキンソン ヘルスケア システムズ エルエルシーＳｔｏｐａｒｋｉｎｓｏｎ Ｈｅａｌｔｈｃａｒｅ Ｓｙｓｔｅｍｓ Ｌｌｃ | 筋肉の場所の識別および治療反応の増強において有効な電気刺激装置 |
| CN109803717B (zh) | 2016-08-25 | 2024-01-09 | 卡拉健康公司 | 通过周围神经刺激治疗心脏机能障碍的系统和方法 |
| EP3606604A4 (en) | 2017-04-03 | 2020-12-16 | Cala Health, Inc. | PERIPHERAL NEUROMODULATION SYSTEMS, METHODS AND DEVICES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH BLADDER HYPERACTIVITY |
| US11857778B2 (en) | 2018-01-17 | 2024-01-02 | Cala Health, Inc. | Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation |
| WO2020068830A1 (en) | 2018-09-24 | 2020-04-02 | Vivek Sharma | Auricular nerve stimulation to address patient disorders, and associated systems and methods |
| US20230414928A1 (en) | 2022-05-20 | 2023-12-28 | Spark Biomedical, Inc. | Devices and methods for treating stress and improving alertness using electrical stimulation |
| US11351370B2 (en) | 2018-12-10 | 2022-06-07 | Spark Biomedical, Inc. | Devices and methods for treating cognitive dysfunction and depression using electrical stimulation |
| US11623088B2 (en) | 2018-12-10 | 2023-04-11 | Spark Biomedical, Inc. | Devices and methods for the treatment of substance use disorders |
| US12502527B2 (en) | 2018-12-10 | 2025-12-23 | Spark Biomedical, Inc. | Devices and methods for treating stress and improving alertness using electrical stimulation |
| CN111494798B (zh) * | 2019-01-31 | 2023-08-11 | 山东上医悦生健康服务有限公司 | 一种耳迷走神经刺激仪及耳迷走神经刺激方法 |
| AU2020234681B2 (en) * | 2019-03-08 | 2025-09-25 | Cala Health, Inc. | Wearable peripheral nerve stimulation for the treatment of diseases utilizing rhythmic biological processes |
| US20220409847A1 (en) * | 2019-06-17 | 2022-12-29 | Evren Technologies, Inc. | Ear device and paired treatments involving nerve stimulation |
| EP3996805B1 (en) * | 2019-07-12 | 2024-03-06 | Starkey Laboratories, Inc. | Systems for treating equilibrium disorders and improving gait and balance |
| WO2021011165A1 (en) * | 2019-07-14 | 2021-01-21 | Spark Biomedical, Inc. | Systems and methods for delivering therapy using an auricular stimulation device |
| US12251560B1 (en) | 2019-08-13 | 2025-03-18 | Cala Health, Inc. | Connection quality determination for wearable neurostimulation systems |
| US11241574B2 (en) * | 2019-09-11 | 2022-02-08 | Bose Corporation | Systems and methods for providing and coordinating vagus nerve stimulation with audio therapy |
| US11235156B2 (en) * | 2019-09-11 | 2022-02-01 | Bose Corporation | Wearable audio device with vagus nerve stimulation |
| GB2604264B (en) * | 2019-09-20 | 2023-11-29 | Neurotone Australia Pty Ltd | Medical treatment device and method of operation thereof |
| US11890468B1 (en) | 2019-10-03 | 2024-02-06 | Cala Health, Inc. | Neurostimulation systems with event pattern detection and classification |
| EP4054407B1 (en) * | 2019-11-08 | 2026-04-29 | United Therapeutics Corp. | Stimulation devices and systems |
| US12390659B2 (en) * | 2019-11-12 | 2025-08-19 | Lew Lim | Apparatus and method for photobiomodulation-based alternative to electrical vagus nerve stimulation and deep brain stimulation related to movement disorders |
| PT3693053T (pt) * | 2019-11-20 | 2022-03-25 | Xanastim Sarl | Dispositivo e sistema de neuroestimulação auricular |
| WO2021262789A1 (en) | 2020-06-23 | 2021-12-30 | Bose Corporation | Haptic tinnitus therapeutic system |
| EP4182011A4 (en) * | 2020-07-17 | 2024-06-19 | United States Government as represented by the Department of Veterans Affairs | Devices, systems, and methods for auricular vagus nerve stimulation |
| GB202011523D0 (en) * | 2020-07-24 | 2020-09-09 | Univ London Queen Mary | Neuromodulation for the treatment of critical illness |
| GB202011522D0 (en) * | 2020-07-24 | 2020-09-09 | Afferent Medical Solutions Ltd | Neuromodulation for the treatment of circulatory system diseases |
| CN111904404B (zh) * | 2020-08-06 | 2021-06-18 | 苏州国科医工科技发展(集团)有限公司 | 含闭环监测的基于耳迷走神经刺激的血压调控设备 |
| WO2022067128A2 (en) | 2020-09-25 | 2022-03-31 | Medtronic, Inc. | Minimally invasive leadless neurostimulation device |
| CN116367888A (zh) | 2020-09-25 | 2023-06-30 | 美敦力公司 | 微创无引线神经刺激装置 |
| NO20201159A1 (en) * | 2020-10-23 | 2022-04-25 | Euronlabs As | Device for treating long-term or chronic pain through vagus nerve stimulation and use thereof |
| CN112354085A (zh) * | 2020-11-20 | 2021-02-12 | 张文赞 | 一种耳部迷走神经刺激系统 |
| CN116547034A (zh) * | 2020-12-11 | 2023-08-04 | 株式会社资生堂 | 美容设备以及使用该美容设备的美容方法 |
| TR202022374A1 (tr) * | 2020-12-30 | 2022-07-21 | Vagustim Saglik Teknolojileri Anonim Sirketi | Hastalik ve rahatsizliklarin tedavi̇si̇nde auri̇küler vagus si̇ni̇ri̇ni̇n kesi̇kli̇ doğru akim i̇le uyarildiği bi̇r si̇stem ve yöntem |
| KR20230146016A (ko) * | 2021-01-12 | 2023-10-18 | 주식회사 에스알파테라퓨틱스 | 관절염 치료를 위한 디지털 장치 및 방법 |
| US12440679B2 (en) * | 2021-02-24 | 2025-10-14 | Medtronic, Inc. | Electric stimulation system |
| WO2022221644A2 (en) | 2021-04-16 | 2022-10-20 | Texas Medical Center | Systems and methods for stimulating two or more nerve branches |
| CN113197587A (zh) * | 2021-04-26 | 2021-08-03 | 中国科学院深圳先进技术研究院 | 一种用于迷走神经刺激和电生理检测的装置及植入方法 |
| WO2022255962A1 (en) * | 2021-05-31 | 2022-12-08 | Vagustim Saglik Teknolojileri Anonim Sirketi | A system and method for optimizing nerve stimulation parameters based on changes in the voice of a patient |
| WO2022255961A1 (en) * | 2021-05-31 | 2022-12-08 | Vagustim Saglik Teknolojileri Anonim Sirketi | A system and method for treating diseases and illnesses through nerve stimulation personalized according to iris mapping of patients |
| TWI773436B (zh) * | 2021-07-15 | 2022-08-01 | 國立成功大學 | 耳廓經皮神經刺激器 |
| WO2023023707A1 (en) * | 2021-08-21 | 2023-03-02 | Mcfarlane Wade | A closed loop control in-ear wearable electroceutical |
| KR102649949B1 (ko) * | 2021-10-18 | 2024-03-22 | 주식회사 뉴라이브 | 미주신경 자극장치 |
| EP4197586B1 (de) * | 2021-12-20 | 2025-01-29 | Hahn-Schickard-Gesellschaft für angewandte Forschung e. V. | Personalisiertes elektroden-interface zur aurikulären stimulation |
| CN114404803A (zh) * | 2022-01-05 | 2022-04-29 | 清华大学 | 迷走神经刺激仪及迷走神经刺激方法 |
| US20250229086A1 (en) | 2022-01-20 | 2025-07-17 | Setpoint Medical Corporation | Treatment of inflammatory disorders |
| US12017068B2 (en) | 2022-05-27 | 2024-06-25 | Spark Biomedical, Inc. | Devices and methods for treating motion sickness using electrical stimulation |
| CN115137312B (zh) * | 2022-08-31 | 2023-01-24 | 首都医科大学附属北京同仁医院 | 睡眠质量评估方法、装置及穿戴设备 |
| GB2628593B (en) * | 2023-03-29 | 2025-05-14 | Toumazou Christofer | Vagus nerve stimulation system and method |
| US12029893B1 (en) | 2023-06-14 | 2024-07-09 | Spark Biomedical, Inc. | Wearable auricular neurostimulator and methods of use |
| EP4578487A1 (en) * | 2023-12-28 | 2025-07-02 | Xana Stim Sárl | A system for bilateral auricular nerve stimulation of the vagus nerve |
| WO2025153924A1 (en) * | 2024-01-16 | 2025-07-24 | Cochlear Limited | Implantable sensor device |
| CN118078242B (zh) * | 2024-04-29 | 2024-06-18 | 北京大学第三医院（北京大学第三临床医学院） | 一种基于毫米波的交感神经功能监测与调控一体化装置 |
| DE102024117735A1 (de) * | 2024-06-24 | 2025-12-24 | Biolitec Holding Gmbh & Co Kg | Tragbare Vorrichtung zur elektrischen Stimulation von mindestens einem und/oder mehreren Nerven eines Benutzers und Verfahren zum Betreiben einer tragbaren Vorrichtung |
| US20260090757A1 (en) * | 2024-09-27 | 2026-04-02 | David C. Shaw | Wearable electrocardiogram (ecg) monitoring systems and automatic anti-arrhythmia systems |
| CN119113398A (zh) * | 2024-11-14 | 2024-12-13 | 杭州神络医疗科技有限公司 | 一种用于治疗膀胱过度活动症的胫神经刺激装置及系统 |
| CN119908672A (zh) * | 2025-04-02 | 2025-05-02 | 上海爱楷医疗科技有限公司 | 一种经皮神经场迷走神经刺激诊疗设备及其诊疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5335657A (en) * | 1991-05-03 | 1994-08-09 | Cyberonics, Inc. | Therapeutic treatment of sleep disorder by nerve stimulation |
| US9089691B2 (en) * | 2004-12-07 | 2015-07-28 | Cardiac Pacemakers, Inc. | Stimulator for auricular branch of vagus nerve |
| DE102005003735B4 (de) * | 2005-01-26 | 2008-04-03 | Cerbomed Gmbh | Vorrichtung zur transkutanen Stimulation eines Nervs des menschlichen Körpers |
| US20080077200A1 (en) * | 2006-09-21 | 2008-03-27 | Aculight Corporation | Apparatus and method for stimulation of nerves and automated control of surgical instruments |
| US9037247B2 (en) * | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
| DE102006023824B4 (de) * | 2006-05-20 | 2010-01-28 | Cerbomed Gmbh | Vorrichtung zur transkutanen Aufbringung eines Reizes oder zur transkutanen Erfassung eines Parameters |
| US9662490B2 (en) * | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US9248286B2 (en) * | 2009-03-20 | 2016-02-02 | ElectroCore, LLC | Medical self-treatment using non-invasive vagus nerve stimulation |
| KR20140037803A (ko) * | 2010-12-14 | 2014-03-27 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 의료 질환 치료용 장치, 시스템 및 방법 |
| US9415220B1 (en) * | 2012-07-31 | 2016-08-16 | Synchromax, Inc. | Auricular stimulation for inflammatory parasympathetic diseases |
| US9242085B2 (en) * | 2013-06-28 | 2016-01-26 | Boston Scientific Neuromodulation Corporation | Transcutaneous electrical stimulation for treating neurological disorders |
| US20160263376A1 (en) * | 2013-11-27 | 2016-09-15 | The Governing Council Of The University Of Toronto | Systems and methods for improved treatment of overactive bladder |
| KR20170063440A (ko) * | 2014-05-25 | 2017-06-08 | 하이인 에쿼티 인베스트먼트 펀드 엘.피. | 웨어러블 경피 신경자극기들 |
| DE102014010882A1 (de) * | 2014-07-27 | 2016-01-28 | Cerbomed Gmbh | Vorrichtung zur Aufbringung eines transkutanen elektrischen Stimulationsreizes |
| WO2016109851A1 (en) * | 2015-01-04 | 2016-07-07 | Thync, Inc. | Methods and apparatuses for transdermal stimulation of the outer ear |
-
2018
- 2018-06-26 JP JP2020520435A patent/JP2020525252A/ja active Pending
- 2018-06-26 CN CN201880055626.9A patent/CN111447969A/zh active Pending
- 2018-06-26 EP EP18825384.3A patent/EP3618919A4/en not_active Withdrawn
- 2018-06-26 WO PCT/US2018/039467 patent/WO2019005774A1/en not_active Ceased
- 2018-06-26 AU AU2018290766A patent/AU2018290766A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/723,833 patent/US20200261722A1/en not_active Abandoned
-
2021
- 2021-07-19 US US17/379,905 patent/US20210346696A1/en not_active Abandoned
-
2022
- 2022-02-14 US US17/651,046 patent/US20220168568A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220168568A1 (en) | 2022-06-02 |
| WO2019005774A1 (en) | 2019-01-03 |
| EP3618919A4 (en) | 2021-01-27 |
| CN111447969A (zh) | 2020-07-24 |
| US20210346696A1 (en) | 2021-11-11 |
| EP3618919A1 (en) | 2020-03-11 |
| JP2020525252A (ja) | 2020-08-27 |
| US20200261722A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220168568A1 (en) | Peripheral nerve stimulation device for affecting parasympathetic and sympathetic activity to achieve therapeutic effects | |
| US12186557B2 (en) | Auricular nerve stimulation to address patient disorders, and associated systems and methods | |
| US12144987B2 (en) | Methods and apparatuses for transdermal stimulation of the outer ear | |
| US20250170396A1 (en) | Methods of adjusting treatment based upon patient activity level | |
| CN108697890B (zh) | 一种通过同步激活神经治疗各种神经疾病的系统和方法 | |
| US11324916B2 (en) | Devices and methods for the non-invasive transcutaneous neurostimulation of the neck and ear vagus nerves via electrical, magnetic and haptic stimulation | |
| EP4299107B1 (en) | Systems for delivering therapy using an auricular stimulation device | |
| US20200338348A1 (en) | Multimodal Transcutaneous Auricular Stimulation System Including Methods and Apparatus for Self Treatment, Feedback Collection and Remote Therapist Control | |
| WO2022221858A2 (en) | Auricular device for nerve stimulation and methods of operating same | |
| US20170165485A1 (en) | Systems and methods for non-invasive treatment of head pain | |
| US20220118253A1 (en) | Systems and methods for craniocervical and auricular neuromodulation | |
| US20210046312A1 (en) | Devices, systems and methods for synchronous binaural vestibular nerve stimulation | |
| US20210290958A1 (en) | Systems, devices and methods for anxiety treatment using vestibular nerve stimulation | |
| KR20260042075A (ko) | 신경조절 시스템 | |
| US20250345605A1 (en) | Devices, systems and methods for enhancing sleep | |
| US20260061154A1 (en) | Systems and methods for nerve stimulation | |
| NO20240902A1 (en) | A wearable electronic stimulating device, a method for operating a wearable electronic stimulating device and a system for operating a wearable electronic stimulating device | |
| WO2026052744A1 (en) | A wearable electronic stimulating device, a method for operating a wearable electronic stimulating device and a system for operating a wearable electronic stimulating device | |
| JP2025536251A (ja) | 経皮的耳介枝迷走神経刺激用ニューロ刺激装置およびシステム | |
| WO2024241067A1 (en) | A vagus nerve stimulation apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: NESOS CORP. Free format text: FORMER NAME(S): VORSO CORP. |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NEXTSENSE, INC. Free format text: FORMER APPLICANT(S): NESOS CORP. |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |